Addex Therapeutics Ltd ADR Dossier
Qualitative Analysis
Business overview
Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of an emerging class of novel, orally available small-molecule drugs known as allosteric modulators for neurological disorders. The company's proprietary platform targets G-protein coupled receptors (GPCRs) and other proteins essential for therapeutic intervention. Addex's pipeline includes clinical and preclinical programs such as dipraglurant (an mGlu5 negative allosteric modulator) being repositioned for brain injury recovery, ADX71149 (an mGlu2 positive allosteric modulator) for epilepsy, and independent GABAB PAM programs for chronic cough.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Repositioning the lead drug candidate dipraglurant (an mGlu5 negative allosteric modulator) from psychiatric indications to brain injury recovery, specifically targeting post-stroke and traumatic brain injury recovery.
Expected impact: Aims to address significant unmet medical needs in post-stroke recovery, leveraging a strong patent position and preclinical collaborations.
Advancing an independent GABAB positive allosteric modulator (PAM) program specifically for the treatment of chronic cough.
Expected impact: Establishes a proprietary clinical candidate in a high-value respiratory indication, supported by robust preclinical anti-tussive data.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Validates Addex's GABAB PAM platform. Indivior has successfully advanced a GABAB PAM candidate for substance use disorders through IND-enabling studies.
Terms: Addex is eligible for milestone payments of up to USD 330 million upon successful achievement of regulatory, clinical, and commercial milestones, plus tiered royalties ranging from high single digits to low double-digits on net sales.
Secures access to additional intellectual property covering the use of mGlu5 negative allosteric modulators (NAMs) in brain injury recovery.
Terms: Exclusive option to license intellectual property to support the clinical repositioning of dipraglurant.